Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04332653 |
| Title | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | NeoImmuneTech |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Moffit Cancer Center | Tampa | Florida | 33612 | United States | Details | |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | United States | Details | |
| Washington University School of Medicine in St. Louis | Saint Louis | Missouri | 63110 | United States | Details | |
| Duke University Medical Center | Durham | North Carolina | 27710 | United States | Details | |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | United States | Details | |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37211 | United States | Details | |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | United States | Details | |
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details |